# PLLA Biostimulators Compared: What Separates the Available Options?

Poly-L-lactic acid (PLLA) biostimulators all share one mechanism — resorbable PLLA microparticles trigger fibroblasts to build new collagen over weeks, producing gradual, long-lasting densification and lift. What actually separates the products on the market is everything around that mechanism: PLLA dose per vial, vial and reconstitution format, added ingredients, published longevity and price position. This article compares the options a European clinic realistically evaluates in 2026: Sculptra®, Gana V/X, Rennova Elleva and Reju PLLA.

All third-party specifications below come from the manufacturers' published materials; trademarks are used nominatively, for identification only. **Sculptra® is a registered trademark of Galderma** ; Alva Medica is not affiliated with Galderma. Alva Medica is the official distributor of the MedRoyal portfolio, which includes Rennova Elleva, Gana and Reju — a commercial relationship readers should weigh as they read.

## How does PLLA biostimulation work, in one paragraph?

Injected PLLA microparticles act as a controlled stimulus in the dermis or subdermis: as the material slowly degrades to lactic acid over months, fibroblasts respond with new type-I collagen around each particle. The visible result — density, firmness, gradual volumisation — emerges over 4–8 weeks per session and consolidates across a short series, which is why every PLLA product shares the same consultation script: nothing dramatic on day one, structural change over the following weeks, results measured in years. Where PLLA sits versus HA fillers and other stimulators is mapped in our [biostimulators vs fillers](/en/blog/biostimulators-vs-fillers) guide.

## What are the main PLLA products and their published formats?

Figures below are from manufacturer-published data; verify against the current IFU of each product before clinical use.

| Product | PLLA content per vial | Format | Published longevity | Composition notes |
|---|---|---|---|---|
| Sculptra® | ~150 mg  | Lyophilised powder, reconstitution with sterile water per IFU | Up to ~2 years per manufacturer materials  | PLLA with carboxymethylcellulose and mannitol excipients  |
| Gana V | 210 mg | 15 ml vial | 2–3 years | Pure PLLA |
| Gana X | 630 mg | 40 ml vial | 2–3 years | Pure PLLA |
| Rennova Elleva 210 | 210 mg | Lyophilised vial for reconstitution | 24–36 months | Pure PLLA |
| Rennova Elleva 630 | 630 mg | Lyophilised vial for reconstitution | 24–36 months | Pure PLLA |
| Reju PLLA | 365 mg combined PLLA + PN | Vial for reconstitution | Up to 24 months | PLLA + polynucleotides (two-phase effect) |

Three structural patterns stand out. First, the 210/630 mg dose tiering used by both Gana and Rennova Elleva creates a clean split between facial-zone work (210 mg) and full-face or body programmes (630 mg), where per-session consumption is several times higher. Second, Reju PLLA is the composition outlier: its polynucleotide fraction produces a gentle, immediately visible filling effect on day one, closing the "nothing happened" gap that pure PLLA consultations must manage. Third, all of them are professional-use products for qualified practitioners — distribution runs through verified B2B accounts, never retail.

## Which format fits which clinic workload?

Dose economics drive the choice more than brand debates. A clinic doing occasional single-zone facial PLLA (temples, cheeks) is served by a 210 mg tier — Rennova Elleva 210 or Gana V. High-volume practices and body-zone programmes (abdomen, buttocks, thighs, décolleté) burn PLLA fast enough that the 630 mg formats become the economical default. Practices whose patients struggle with the delayed-result conversation have a specific reason to look at Reju PLLA: the PN phase gives the patient something to see immediately while the collagen phase builds.

Reconstitution practice differs by product — hydration times, final volumes and dilution schemes are IFU-level parameters, and the biggest operational differences between brands show up here rather than in the syringe. Whichever product you stock, the post-session massage discipline and deep injection plane are non-negotiable across the category.

## What does the comparison mean commercially?

For a European buyer, the practical short-list question is usually price-per-milligram of PLLA at your realistic order volume, weighed against reconstitution workflow and patient-facing differentiators (the PN phase, published longevity, brand recognition in your market). As official MedRoyal distributor, Alva Medica quotes Rennova Elleva, Gana and Reju individually per market and volume — browse the [biostimulators category](/en/produkty/biostymulatory), or request [wholesale terms](/en/hurtownia) if you buy for a clinic group or resale territory.

## FAQ

### Is a higher PLLA content per vial always better?

No — it is a workload match, not a quality ranking. A 630 mg vial only wins economically if your case mix consumes it within its post-reconstitution usability window; for occasional facial work, a 210 mg tier avoids waste and simplifies dosing discipline.

### How is Reju PLLA different from pure-PLLA products?

Reju combines 365 mg of PLLA with polynucleotides in one preparation. The PN fraction gives an immediate light filling and its own regenerative contribution; the PLLA fraction delivers the long-term collagen phase. Pure-PLLA products concentrate everything in the delayed structural phase.

### How long do PLLA results actually last?

Manufacturer-published figures across the category cluster at roughly two to three years: Gana and Rennova Elleva publish 2–3 years / 24–36 months, Reju up to 24 months, and Sculptra®'s manufacturer has published results out to about two years.  Individual duration varies with age, zone, metabolism and dosing.

### Who is allowed to inject PLLA biostimulators?

Qualified aesthetic-medicine practitioners only. These are deep-plane, technique-sensitive products; as distributor we verify professional status during B2B onboarding before first supply, and every clinic should document batch numbers per patient as standard practice.

---

*All third-party product information above is based on manufacturer-published data at the time of writing; nominative trademark use only, no affiliation or endorsement implied. This article compares products factually and makes no claim of clinical superiority of any product over another. Last updated: 2026-08-11.*

---

Alva Medica — canonical page: https://alvamedica.com/en/blog/plla-biostimulators-compared